#Kyoto #Regenesome #Nanoparticles #IVS2026

Regenesome to Exhibit at IVS2026

Regenesome, a subsidiary of Space Seed Holdings, has confirmed its participation in IVS2026, Japan's largest startup conference, scheduled from July 1 to 3, 2026, at the Miyakome Messe in Kyoto. Specifically, Regenesome will showcase its developments during Day 2 of the event on July 2, 2026, at booth SA-33. This participation is seen as a significant step in their mission to implement age control and regenerative medicine through nanoparticle technology.

About the Event

IVS2026, an event organized by Headline Japan, brings together some of the leading startups in the country to discuss innovation and collaboration. Regenesome views this participation as an opportunity to engage directly with investors, businesses, research institutions, and potential partners. The focus will be on communicating their advancements in nanotechnology aimed at controlling aging and fostering dialogue on its societal applications.

Regenesome's Vision and Mission

Regenesome is dedicated to addressing age-related challenges through biotechnology. Their mission is to develop applications of liposomes and nanoparticles to combat aging and establish regenerative medicine. They aim to create age-defying technologies that could facilitate human habitation on the Moon by 2040. Their innovative vision encompasses validating aging prevention technology by 2030 to enhance health longevity on Earth.

At IVS2026, Regenesome is set to introduce its research direction while discussing possible applications to both aging issues on the ground and future ventures in space healthcare. This is part of their broader goal of connecting longevity research with advancements in outer space health.

Future Initiatives

In line with the opportunities presented at the IVS Startup Market, Regenesome plans to:

• - Foster discussions with corporate investment arms, CVCs, and VCs within the longevity and regenerative medicine sectors.
• - Open dialogues for collaborative research and business partnerships to further the social implementation of their nanoparticle technology.
• - Continue initiatives connecting health longevity research from Earth to space healthcare applications.

Details on specific collaborations will be unveiled as agreements are finalized with respective parties.

About Regenesome Inc.

Regenesome is dedicated to providing innovative solutions focused on age suppression and regenerative healthcare through nanoparticle technology. They have established their headquarters and research institute at the Takanawa Gateway City, known as the Takanawa Longevity Lab. Additionally, they are launching their healthcare services under their brand